TNF Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
TNF Pharmaceuticals has been growing earnings at an average annual rate of 7.9%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually.
Key information
7.9%
Earnings growth rate
16.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | n/a |
| Return on equity | -120.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How TNF Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -18 | 9 | 8 |
| 31 Dec 23 | 0 | -8 | 8 | 8 |
| 30 Sep 23 | 0 | -7 | 8 | 7 |
| 30 Jun 23 | 0 | -14 | 8 | 7 |
| 31 Mar 23 | 0 | -13 | 6 | 7 |
| 31 Dec 22 | 0 | -15 | 6 | 9 |
| 30 Sep 22 | 0 | -15 | 7 | 7 |
| 30 Jun 22 | 0 | -16 | 7 | 9 |
| 31 Mar 22 | 0 | -31 | 22 | 8 |
| 31 Dec 21 | 0 | -30 | 21 | 7 |
| 30 Sep 21 | 0 | -31 | 22 | 7 |
| 30 Jun 21 | 0 | -29 | 22 | 5 |
| 31 Mar 21 | 0 | -12 | 6 | 4 |
| 31 Dec 20 | 0 | -9 | 6 | 2 |
| 31 Dec 19 | 0 | -10 | 6 | 4 |
Quality Earnings: 0A8D is currently unprofitable.
Growing Profit Margin: 0A8D is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0A8D is unprofitable, but has reduced losses over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare 0A8D's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0A8D is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).
Return on Equity
High ROE: 0A8D has a negative Return on Equity (-119.99%), as it is currently unprofitable.